Nonetheless, clinical trials that are currently being explored with antibodies targeting the CD47-SIRPα axis from the CD47 side in combination with tumor-specific monoclonal antibody therapy have shown minimal to moderate toxicity effects [36,37,38]. This evidence concerns the gene CD47 and neoplasm.